A call to action for improving clinical outcomes in patients with asthma
- PMID: 33277487
- PMCID: PMC7718279
- DOI: 10.1038/s41533-020-00211-x
A call to action for improving clinical outcomes in patients with asthma
Conflict of interest statement
A.M. has received honoraria for attending advisory boards, providing continuing medical education and participating in clinical trials as an investigator from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Merck and Novartis. A.K. received non-financial support from AstraZeneca during the conduct of the study; personal fees from AstraZeneca, Covis, GlaxoSmithKline, Novo Nordisk, Novartis, Pfizer, Purdue, Sanofi and Teva; and personal fees and non-financial support from Boehringer Ingelheim, Pfizer, Novartis and Trudell, outside the submitted work. The meetings and outputs of the Steering Group are funded by AstraZeneca, as part of activities seeking to encourage solutions to improve asthma management across all stakeholders. MHP Communications, whose services are also paid for by AstraZeneca, supports with the administration and running of the Steering Group. Participation in the Steering Group was not financially supported by AstraZeneca.
Figures
References
-
- Global Asthma Network (GAN). The Global Asthma Report. http://www.globalasthmareport.org (2018).
-
- Conference Board of Canada. Cost Risk Analysis for Chronic Lung Disease in Canada. https://www.conferenceboard.ca/temp/3d4bc04b-9f21-4b67-98e3-1fd49ff48297... (2012).
-
- Kotwani A. Availability, price and affordability of asthma medicines in five Indian states. Int. J. Tuberc. Lung Dis. 2009;13:574–579. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
